E I Du Pont De Nemours And Co (DD): Will a Good Earnings Report Turbocharge This Stock?

Page 1 of 2

E I Du Pont De Nemours And Co (NYSE:DD) investors have been a disappointed lot lately. The stock has lost 7% over the past year, and is still finding it hard to move up even as the Dow rallies to new highs. A major announcement some weeks back couldn’t give its shares a much needed fillip, though the event is largely in E I Du Pont De Nemours And Co (NYSE:DD)’s favor.

The chemical maker will be put to another test next week when it suits up with its first-quarter report. It’s time DuPont put up some solid numbers on the board if it wants to bounce back in the game. Its chances, however, look grim.

Where’s all the excitement gone?

Analysts are looking at flattish year-over-year earnings per share of $1.52 on 7% lower revenue. Those who relished Monsanto Company (NYSE:MON)’s recent blowout numbers might expect DuPont to do well too. After all, DuPont is more of an agriculture play now than a chemicals one. Monsanto Company (NYSE:MON) reported an impressive 15% jump in its last-quarter revenue, backed by a 16% rise in corn seed and trait sales and solid business in Latin America. DuPont stands to gain too, and I am 100% sure that agriculture will be its top-performing segment in the first quarter. But the good news will probably end there.

Even if DuPont pulls off a decent quarter, it’s unlikely it will improve its outlook for the year, unlike Monsanto Company (NYSE:MON). A solid second quarter encouraged Monsanto to raise its 2013 expected EPS by $0.10 on both ends of the range. So even at the lower end, that would mean a neat 19% climb from 2012 EPS. In contrast, E I Du Pont De Nemours And Co (NYSE:DD) expects an unexciting 7% improvement even at the higher end of its earnings guidance. I am not expecting an improvement for two reasons. One, agriculture is just about a third of DuPont’s revenue, and two, its other businesses are still coping with macro challenges.

Murky waters

Demand for titanium dioxide pigment (TiO2), which is also DuPont’s key product, started slipping during the second half of last year, leaving DuPont and peers in the lurch. DuPont is desperately waiting for the weakness to end. Unfortunately, going by what DuPont said in its last earnings call, a comeback is unlikely this year. E I Du Pont De Nemours And Co (NYSE:DD) projected lower sales and 7% to 9% drop in margins for its performance chemicals business for 2013.

DuPont’s peers sound a bit more optimistic though. Huntsman Corporation (NYSE:HUN), for instance, projects both demand and prices of the pigment to bounce back as early as the second quarter this year, which should help its pigments business break even. Huntsman even reported higher pigment volumes in key market Asia during its fourth quarter. That was certainly an encouraging sign. Nevertheless, Huntsman doesn’t expect anything more than $200 million EBITDA (earnings before interest, tax, depreciation, and amortization) from its pigments business this year even if things crawl back to normal. To put it in perspective, Huntsman generated $362 million and $508 million EBITDA from the business in 2012 and 2011, respectively.

I am giving so much weightage to Huntsman Corporation (NYSE:HUN)’s projections because it has proved to be a better judge of the TiO2 market than DuPont in recent times. Keeping that in mind, I have a sneaking feeling that E I Du Pont De Nemours And Co (NYSE:DD)’s margins from performance chemicals might fall more than it expects. This is certainly something I’m going to keep my eyes on when DuPont reports next week, and I’ll make sure I tally that up with Huntsman Corporation (NYSE:HUN)’s outlook when it releases earnings at the end of the month.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!